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The turnaround time (TAT) for pre-transfusion testing is 
important for prompt clinical decision-making. TAT includes 
the time between the arrival of the sample and the initiation of 
testing, plus the processing time (PT) required to generate and 
report a result. The TAT in larger blood banks is mostly dependent 
upon the capability of the analyzer used. In smaller blood banks, 
where manual work is often performed, the TAT is dependent 
on availability and experience of staff, testing resources, and 
workload. Our site performed a comparative analysis of the 
ORTHO VISION® (Ortho Clinical Diagnostics, Raritan, NJ) and 
the Echo® (Immucor, Norcross, GA) blood bank analyzers, using 
the TAT and PT of standard blood bank tests as the outcome 
metrics. Tests were run in various combinations to reflect the 
standard workflow of a busy hospital transfusion service and 
under routine and immediate or STAT conditions. We also 
compared manual versus automated processing TATs for a variety 
of pre-transfusion tests and antibody titers. We found that the 
capacity of the VISION to load and run new samples, even while 
several other tests were ongoing, allowed for faster overall TAT 
when compared with samples run on the Echo. The PTs of the two 
analyzers (from load to result) were also compared, and we found 
them to be equivalent. These findings highlight the inherent flaw 
in considering only PT when assessing a laboratory’s ability to 
efficiently and consistently make results available to best meet 
customer and patient needs. In addition, we observed a tighter 
distribution of TATs and PTs when the VISION was compared 
with the Echo analyzer, providing a higher level of predictability 
for availability of results. Finally, when compared with manual 
antibody titer testing, the VISION analyzer showed a faster PT. 
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Short turnaround times (TATs) that do not compromise 
the precision or accuracy of red blood cell (RBC) phenotyping 
and antibody detection is of utmost importance in the practice 
of blood banking. Serologic testing for antigens on RBCs 
and screening for antibodies have transitioned from time-
consuming manual methods, beset with both inter- and intra-
tester variabilities, to testing via automated analyzers that 
show improvement on many parameters.
We define TAT as the time between sample arrival and 
result availability, as it most accurately reflects the needs of 
clinicians and patients. Additionally, we define processing 
time (PT) as the time from when work is begun on a sample, 
whether by manual testing or by loading it onto an analyzer, to 
its result availability.
The main aim of this study was to compare the TATs of two 
blood bank analyzers, the ORTHO VISION® (Ortho Clinical 
Diagnostic, Raritan, NJ) and that of the Echo® (Immucor, 
Norcross, GA), by using representative patient samples 
normally seen in a busy, high-complexity hospital transfusion 
service. To improve efficiency by decreasing reagent waste, 
samples for the Echo were usually batched prior to running. In 
contrast, no batching was used with the VISION, since it has a 
“load as you go” feature, which allows the introduction of new 
samples even while the analyzer is in mid-cycle with other 
tests. Therefore, a secondary aim of this study was to decrease 
reagent wastage while maintaining a quick TAT.
Materials and Methods
Between January 4 and January 12, 2016, the University 
of Minnesota Medical Center blood bank laboratory ran type 
and screens, antibody identifications, crossmatches, direct 
antiglobulin tests (DATs [both polyspecific and monospecific 
IgG]), and anti-A and anti-B titers on blood samples using 
the Immucor Echo, the ORTHO VISION, and manually, for 
a total of 437 individual tests. Samples were collected on two 
randomly selected dates during 6-hour windows beginning at 
0700 when operating room cases began, since this represented 
the busiest times in the blood bank. All samples that arrived 
during this 6-hour time frame were run on both analyzers, 
per the manufacturers’ instructions. All samples were from 
individual patients except for corresponding antibody workups 
on those with positive antibody detection tests.  Reagents 
used on the VISION included 0.8 percent Surgiscreen (screen 
cells 1,2,3), Affirmagen A1 and B Cells, MTS Diluent 2, MTS 
Diluent 2 PLUS, 0.8 percent Resolve Panel A and Panel B, and 
0.8 percent Affirmagen Cells (Ortho Clinical Diagnostics). 
Reagents used on the Echo included Anti-A, Anti-B, Anti-D, 
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and Monoclonal Control; A1 and B Cells; Ready ID; Extend 
I and Extend II strips for panels; CMT strips for type and 
screens; and DAT strips for autocontrols (Immucor).
For efficient use of reagents, it was standard practice for 
the laboratory to collect a full batch of samples prior to loading 
and running the Echo. The Echo can run a minimum of one 
sample and maximum of 20 per batch. Because the VISION 
has the capability to load and run samples as they arrive in 
the lab, batching is not required to avoid reagent wastage, 
and therefore was not used. The data for each method were 
recorded and compared in three ways: (1) TAT using samples 
tested with the VISION versus the Echo, (2) PT of the VISION 
versus the Echo, and (3) PT of the VISION versus a manual 
method.
The manual methods of ABO and D typing and DAT 
(both monospecific IgG and polyspecific) were performed 
by tube method. Manual indirect antibody detection testing 
and anti-A and anti-B titer levels were performed by column 
agglutination using ID-Micro Typing System (MTS) Gel 
Test (Ortho Clinical Diagnostics). All manual methods were 
performed in accordance with AABB standards. Tests were 
completed under routine and immediate or STAT conditions 
to include analysis of TATs that were representative of busy 
and slow times in the laboratory.  Software for the VISION was 
updated during the testing period to improve the efficiency 
and better allow for analysis of individual samples. Some of 
the tests were run using both the original software and the 
updated software, and these times were also compared. 
Statistical analysis of the time to results (TAT) comparisons 
for the VISION and Echo were performed using Minitab 
17.1.0 (Minitab, State College, PA). The SDs about the mean 
were made assuming a normal distribution. This study was 
approved by the University of Minnesota institutional review 
board.
Results
A total of three analyses were performed. The first analysis 
compared the TATs of the VISION and Echo for routine type 
and screens, crossmatches, and antibody identification. The 
TAT was measured from the arrival time of the sample in the 
laboratory to its result time. To enhance reagent use efficiency, 
samples for the Echo were batched prior to testing; samples for 
the VISION were run as they arrived in the blood bank. TATs 
for a total of 23 type and screens were compared. The mean 
TAT for the Echo was 1:12 (hours:minutes) versus 0:31 for the 
VISION. The mean TAT for crossmatches (N = 4) was almost 
identical (0:34 vs. 0:33 for the Echo and VISION, respectively). 
Similar times were also obtained for antibody identification 
testing (N = 3) (Table 1, Fig. 1). The range of these TATs (N = 
29) showed a tighter distribution in the TAT of the VISION, as 
demonstrated by an SD of 6.59 for the VISION, compared with 
an SD of 18.89 for the Echo. The variation in TAT is largely 
explained by the ability of the VISION to receive and process 
test samples as they arrived without manual intervention. 
By contrast, because of the desire to save resources, samples 
were batched on the Echo, and the associated wait times had a 
negative impact upon TAT.
A second analysis compared the PTs for the VISION 
and Echo for routine and STAT type and screens, routine 
crossmatches, and routine antibody identification using RBC 
panels. The PT for this test cycle was defined as the time from 
loading the sample to the result time. A total of five routine 
type and screens were compared. The mean PT for the Echo 
was 0:29 versus 0:31 for the VISION. The mean PT for STAT 
crossmatches (N = 4) for the Echo was 0:34, and 0:29 for the 
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Table 1. A comparison of turnaround times based on arrival 
pattern*
Test TYSC (N = 22) XM (N = 4) Antibody ID (N = 3)
Analyzer Echo VISION Echo VISION Echo VISION 













Median 0:50 0:29 0:34 0:33 0:31 0:33
*The sample turnaround time was measured from the time the sample 
arrived in the laboratory to when it was resulted. Times are in hours:minutes.
TYSC = type and screen; XM = crossmatch; ID = identification.
Fig. 1 Turnaround time (hours:minutes) based on sample arrival 
pattern for VISION versus Echo. A total of 23 type and screens, 4 
crossmatches, and 3 antibody identifications were compared.
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VISION. The mean PT for routine antibody identifications 
(N = 3) for the Echo was 0:31 and for the VISION was 0:33. 
Eighteen STAT type and screens were run, and the mean PT 
for both the Echo and the VISION was 0:28 (Table 2, Fig. 2). 
The range of PTs for these tests (N = 30) was compared. The 
SD for the Echo was 3.39, versus 2.09 for the VISION.
The third analysis compared the VISION PT to a manual 
PT for routine and STAT type and screens, DAT (both 
monospecific IgG and polyspecific), antibody identification 
by indirect antiglobulin testing with RBC panels, routine 
ABO typing, anti-A and anti-B titers, and crossmatches 
(Table 3). These tests were run sequentially to replicate the 
natural workflow of samples encountered in the blood bank. 
For example, a positive type and screen would be followed 
by RBC panels and crossmatches. This analysis recorded 
the sequential PT, but also noted the time it would take if all 
samples were run in parallel. As expected, the manual PTs 
were longer than the VISION PTs. The PT for the VISION 
to perform an anti-A and anti-B titer was 0:32 each for both 
titers. This same test performed manually took 4:09. When a 
type and screen was followed by two RBC panels (antibody 
ID × 2), a DAT, and a crossmatch, the manual time was 
5:46, whereas the VISION PT was 1:32. If these tests had 
been run simultaneously, the VISION’s PT would have been 
0:33. During this phase of testing, the VISION software was 
updated; using the new software, all test combinations were 
repeated, with greatly improved PTs seen for most tests. These 
data are displayed in the final column of Table 3.
Discussion
Turnaround time is one of the most important metrics 
used to measure a laboratory’s ability to efficiently meet the 
needs of its customers and patients. The VISION’s ability 
to simultaneously load and process different tests (even 
while other samples are running), with minimal human 
intervention, generated faster TATs for delivery of test results. 
This capability gives the VISION a unique advantage over 
Table 2. A comparison of processing times based on load pattern*
Test TYSC Routine (N = 5) XM STAT (N = 4) Antibody ID Routine (N = 3) TYSC STAT (N = 18)
Analyzer Echo VISION Echo VISION Echo VISION Echo VISION
Mean 0:29 0:31 0:34 0:29 0:31 0:33 0:28 0:28
(range) (0:26–0:35) (0:28–0:37) (0:34–0:34) (0:29–0:29) (0:29–0:35) (0:32–0:34) (0:25–0:35) (0:27–0:30)
Median 0:29 0:31 0:34 0:29 0:31 0:33 0:27 0:29 
*The sample processing time was measured from the time the sample was loaded onto the analyzer to when it was resulted. Times are in hours:minutes. 
TYSC = type and screen; XM = crossmatch; ID = identification.
Fig. 2 Processing time (hours:minutes) of VISION versus Echo. 
A total of 5 routine type and screens, 4 crossmatches, 3 antibody 
identifications, and 18 STAT type and screens were compared. 
TYSC = type and screen; XM = crossmatches, ID = identification. 
Table 3. A comparison of processing times for the VISION and 
manual testing, including original and updated software on the 
VISION, using various combinations of tests















R 5:53 0:30 0:31 0:30
TYSC
Antibody ID × 2
DAT-Poly
XM
R 5:46 1:32 0:33 0:32
TYSC
Antibody ID × 1
DAT-Poly
XM × 3
S 6:11 1:57 0:58 0:43
TYSC
Antibody ID × 2
XM
R 2:15 1:51 0:42 0:41
*Updated software version used.
†Original software version used.
Times are in hours:minutes.
R = routine; S = STAT; TYSC = type and screen; DAT = direct antiglobulin 
test; Poly = polyspecific; ID = identification; XM = crossmatch.
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other analyzers that require human intervention to minimize 
waste or otherwise compensate for what is required to make 
the instrument run efficiently. Waiting while a full batch of 
samples is assembled will usually delay the running of the first 
tests that arrive, thereby increasing a sample’s overall TAT.
We compared the TAT of the VISION and Echo from 
sample arrival in the lab to the time the test was completed 
(Table 1, Fig. 1) and the PT of each from load time to test 
completion (Table 2, Fig. 2). Because the VISION load and 
arrival times were simultaneous, VISION had faster TATs 
when compared with those of the Echo. When mean run times 
were compared, the VISION and Echo were equivalent. The 
range of PTs for the VISION was tighter (SD 2.09 vs. 3.39) than 
that seen with the Echo, suggesting that the PT for the VISION 
can be more precisely predicted and is more reproducible 
when compared with the Echo. Additionally, batching tests 
on the Echo may have artificially created a longer TAT, which 
contributed to a wider range of TAT data (SD of VISION 6.59 
vs. Echo 18.89). A statistical comparison of the two analyzers 
was not feasible because of the small sample size of this study.
A final series of tests fully exploited the VISION’s capacity 
to run different kinds of tests simultaneously. We ran type 
and screens, crossmatches, DATs, and antibody panels. The 
PTs were compared when these tests were run sequentially, 
but the longest single test in the group was also noted as the 
minimum run time for group testing. The VISION performed 
each test faster than manual testing when run in parallel, or 
when tested sequentially.
We could not compare the TAT or PT of the two analyzers 
for antibody titer testing because the Echo does not include 
this procedure in its test menu. As expected, the VISION 
determined titers more rapidly than manual testing. Because 
titers are often ordered in hospitals with obstetric and solid-
organ transplant patient populations, the ability to automate 
this labor-intensive test has improved the blood bank’s 
workflow and efficiency. Although this study tested the 
isohemagglutinin titer capacity of the VISION, it may also 
be used to test for anti-D titers, which is often a critical part 
of care for obstetric patients. The study also showed a vast 
improvement in PT for combinations of common lab tests 
(Table 3), which may help expedite TATs as well.
A comparison of analyzers should go beyond the metric of 
overall TAT. Systems that use multi-sample cartridges either 
suffer from prolonged TAT because of the batching of staggered 
samples, or create the potential for wastage of cartridges and 
reagents when only a partial batch is run. This situation was 
readily seen during STAT testing with the Echo. When the 
Echo was running routine tests and a STAT test arrived, the 
STAT test would be loaded individually to generate a quick 
result. Although this step kept the PT and TAT short, reagent 
wastage occurred because the analyzer was using reagents 
for the routine tests and the STAT tests separately. Using an 
analyzer that is designed to run samples individually will 
improve not only TAT but also decrease cartridge and reagent 
waste. 
Studies have shown that gel card testing, as used on the 
VISION, has either superior sensitivity to manual testing1 or 
is at least comparable.2 Our study showed that manual testing 
(conventional tube testing) had inferior TATs compared with 
an automated method. Because gel testing shows similar 
sensitivities as conventional tube testing, these testing 
parameters can be improved upon even further with superior 
TATs, as shown with the VISION.
There were limitations to our study. Because of the small 
number of samples that were run within each testing category, 
statistics could not be applied. Also, not all tests were run 
with the updated software; therefore, some VISION TATs are 
reflective of the former software, whereas others are reflective 
of the updated software. Although our study did not specifically 
look at the consistency of results between each testing method 
(Echo, VISION, and manual), all three methods have been 
validated. The Echo was validated through conventional tube 
testing, since the solid-phase testing had been taken offline.
Overall, our study showed that in a comparative analysis 
of the Ortho Clinical Diagnostic VISION and the Immucor 
Galileo Echo blood bank analyzers, the PT of these analyzers 
was similar, although the “load on the fly” feature of the VISION 
allowed for faster overall TAT and enhanced workflow within 
the blood bank. A tighter distribution of TATs was observed 
with the VISION when compared with the Echo, confirming 
that the VISION’s TATs were more predictable than those of 
the Echo. Finally, the addition of automated isohemagglutinin 
and RBC alloantibody titers make this analyzer a welcome 
addition for busy blood bank laboratories.
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